US Edition
News from dermatologytimes.com
Top dermatologytimes.com News
Health · United StatesA hormone-free male birth control pill passed its first safety test in ongoing clinical trials, marking a major milestone in its development.The results from the early phase 1 clinical trial testing the safety of the daily pill referred to as YCT-529 were published on Tuesday in the journal Communications Medicine.The pill is designed to decrease sperm count by impairing retinoic acid signaling in the testes, according to its San Francisco-based…See the Story
Breakthrough Male Birth Control Pill Passes Safety Test in Early Clinical Trial
75% Center coverage: 12 sources
Missoula · MissoulaThe Missoulian spoke to four students who utilized the free services provided by the center to advance to a college degree, learn English and start a career in nursing.See the Story
'It paid off': Lifelong Learning Center students share success stories after staff cuts
100% Center coverage: 4 sources
FDA · United StatesThe FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license application for vusolimogene oderparepvec in combination with nivolumab for the treatment of advanced melanoma.According to a company press release, the letter indicates that the FDA cannot approve the application for vusolimogene oderparepvec (RP1) — the company’s leadSee the Story
FDA Rejects RP1 for Advanced Melanoma, Says IGNYTE Not a ‘Well-Controlled’ Trial
67% Center coverage: 3 sources
